L-glutamine positive for Emmaus, commercial prospects unclear
This article was originally published in Scrip
Executive Summary
A pharmaceutical-grade L-glutamine developed by Emmaus Life Sciences reduced the frequency of sickle cell crises and hospitalizations in a Phase III clinical trial, but questions remain about the commercial market for a product that's available as an over-the-counter supplement.
You may also be interested in...
Emmaus Sickle Cell NDA Facing FDA Concerns About Clinical Meaningfulness
PGLG's application only has one Phase III trial, and Emmaus is hoping statistical re-analyses can address FDA skepticism about clinical meaningfulness of the primary endpoint data.
Finance Watch: Canaan, Regeneron Reveal New Funds For Start-Ups
Private Company Edition: Regeneron launched a $500m venture fund and Canaan added $100m, bringing the venture firm’s recent total to $1bn-plus. Also, incubators plan to grow over the next decade and in recent financings Avenzo raised $150m and Nvelop launched with $100m.
Sage’s Dalzanemdor Prospects In Doubt After First Mid-Stage Readout
Dalzanemdor (SAGE-718) showed no difference from placebo in a Phase II Parkinson’s disease study, raising concerns about readouts later this year in Huntington’s and Alzheimer’s diseases.